Latest Breaking News On - Helen diller comprehensive cancer center - Page 1 : comparemela.com

Truqap/Faslodex Delays Time to Breast Cancer Progression, Next Therapy

Adding Truqap to Faslodex improved outcomes in patients with locally advanced or metastatic HR-positive, HER2-negative breast cancer.

United statesSan franciscoTruqap faslodexUniversity of californiaDrug administrationBreast cancer congressDepartment of medicineCancer infusion servicesHelen diller comprehensive cancer centerBreast oncologyClinical trials educationHelen diller comprehensive cancer

Capivasertib/Fulvestrant Improves PFS2 in Pretreated PIK3CA/AKT1/PTEN+ HR+/HER2– Breast Cancer

Capivasertib plus fulvestrant improved time to second progression in patients with pretreated HR-positive, HER2-negative advanced breast cancer.

San franciscoUnited statesDepartment of medicineHelen diller comprehensive cancer centerCancer infusion servicesUniversity of californiaBreast cancer congressBreast oncologyClinical trials educationHelen diller comprehensive cancerCancer congress

Pembrolizumab plus olaparib fails to meet dual primary endpoints in breast cancer subset

Pembrolizumab plus olaparib fails to meet dual primary endpoints in breast cancer subset
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

San antonioUnited statesMindy valcarcelByjennifer southallHelen diller comprehensive cancer centerSan antonio breast cancerDiller comprehensive cancer center

Sun-Protective Behaviors Differ Among Asian-American Subgroups

Sun-protective behaviors differ among subgroups of Asian Americans and the differences may help identify those at high risk and inform culturally appropriate interventions, researchers say.

United statesHowa yeungKrittin supapannachartSusana ortiz urdaUniversity of californiaUs national health interviewReuters healthMelanoma programEmory university school of medicineSan francisco helen diller comprehensive cancer centerUs preventive services taskAsian americansFilipino americansEmory university schoolChinese americansIndian americans

Cancer Liquid Biopsy Developer Bluestar Raises $70M, Adds Venter to Scientific Advisory Board

Cancer Liquid Biopsy Developer Bluestar Raises $70M, Adds Venter to Scientific Advisory Board May 21, 2021 J. Craig Venter, Ph.D. Bluestar Genomics, the developer of an epigenomic platform focused on early cancer detection, has raised $70 million in an oversubscribed Series C equity financing and named genomics pioneer J. Craig Venter, Ph.D., among two new members of its expanded scientific advisory board. “Collectively, these milestones will extend our ability to deliver on our promise to improve on existing cancer screening and provide a new solution where none exists,” Samuel Levy, Ph.D., Bluestar’s CEO and Chief Scientific Officer, said in a statement.

Stanford universityUnited statesSan diegoUniversity of california san franciscoSan franciscoStephen quakeChan zuckerberg biohubFelix fengSamuel levyJ craig venterAlan ashworthHelen diller comprehensive cancer centerUniversity of californiaNature communicationsJ craig venter instituteUniversity of chicago